Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR443122 dose-finding study in adults with moderate to severe ulcerative colitis
2022-500290-14-01Phase 2Authorised
- Sponsor
- Sanofi
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial of eclitasertib in autoimmune colitis (3 arms), sponsored by Sanofi. Primary endpoint: Clinical remission at Week 12 by modified Mayo Score. Planned start May 2023; status: authorised.
02
Drugs
eclitasertib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2022-500290-14-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500290-14-01.